TILs recognize neoantigens generated after cancer cell death and elicit an antitumor response through the interaction of distinct T-cell receptors (TCR) with specific neoantigen-derived epitopes presented by MHC molecules [44]. This evidence concerns the gene HLA-C and cancer.